References

Aapro, M., Boccia, R., Leonard, R., Camps, C., Campone, M., Choquet, S.,…Valero, V. (2017). Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: Consensus guidance recommendations. Supportive Care in Cancer, 25(11), 3295–3304. https://doi.org/10.1007/s00520-017-3842-1

Aapro, M., Lyman, G. H., Bokemeyer, C., Rapoport, B. L., Mathieson, N., Koptelova, N.,…Kuderer, N. M. (2021). Supportive care in patients with cancer during the COVID-19 pandemic. ESMO Open, 6(1), 100038. https://doi.org/10.1016/j.esmoop.2020.100038

Aapro, M. S., Bohlius, J., Cameron, D. A., Dal Lago, L., Donnelly, J. P., Kearney, N.,…Zielinski, C. (2011). 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. European Journal of Cancer, 47(1), 8–32. https://doi.org/10.1016/j.ejca.2010.10.013

American Society of Clinical Oncology. (2023). Cancer treatment & supportive care. https://society.asco.org/covid-resources/patient-care-info/cancer-treatment-supportive-care

Amgen Inc. (2021). Neulasta (pegfilgrastim) package insert. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125031s203lbl.pdf

Amgen Inc. (2023). Neupogen (filgrastim) package insert. https://www.pi.amgen.com/-/media/Project/Amgen/Repository/pi-amgen-com/neupogen/neupogen_pi_hcp_english.pdf

Amneal Pharmaceuticals. (2023). Fylnetra (pegfilgrastim-pbbk) package insert. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761084s000lbl.pdf

Andersen, K. M., Bates, B. A., Rashidi, E. S., Olex, A. L., Mannon, R. B., Patel, R. C.,…National COVID Cohort Collaborative Consortium. (2022). Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: A retrospective cohort study using data from the National COVID Cohort Collaborative. The Lancet Rheumatology, 4(1), e33–e41. https://doi.org/10.1016/S2665-9913(21)00325-8

Arvedson, T., O’Kelly, J., & Yang, B. B. (2015). Design rationale and development approach for pegfilgrastim as a long-acting granulocyte colony-stimulating factor. BioDrugs, 29(3), 185–198. https://doi.org/10.1007/s40259-015-0127-4

Averin, A., Silvia, A., Lamerato, L., Richert-Boe, K., Kaur, M., Sundaresan, D.,…Weycker, D. (2021). Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice. Supportive Care in Cancer, 29(4), 2179–2186. https://doi.org/10.1007/s00520-020-05715-3

Barnes, G., Pathak, A., & Schwartzberg, L. (2014). G-CSF utilization rate and prescribing patterns in United States: Associations between physician and patient factors and GCSF use. Cancer Medicine, 3(6), 1477–1484. https://doi.org/10.1002/cam4.344

Bilir, S. P., Ma, Q., Zhao, Z., Wehler, E., Munakata, J., & Barber, B. (2016). Economic burden of toxicities associated with treating metastatic melanoma in the United States. American Health & Drug Benefits, 9(4), 203–213.

Blayney, D. W., & Schwartzberg, L. (2022). Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: A review. Cancer Treatment Reviews, 109, 102427. https://doi.org/10.1016/j.ctrv.2022.102427

Boccia, R., Glaspy, J., Crawford, J., & Aapro, M. (2022). Chemotherapy-induced neutropenia and febrile neutropenia in the US: A beast of burden that needs to be tamed? The Oncologist, 27(8), 625–636. https://doi.org/10.1093/oncolo/oyac074

Broman, K. K., Baez, H., Mihelic, E., Zhu, S., Dineen, S., Fleming, J. B.,…Pimiento, J. M. (2021). Combined use of advanced practice providers and care pathways reduces the duration of stay after surgery for gastrointestinal malignancies. Surgery, 169(4), 852–858. https://doi.org/10.1016/j.surg.2020.06.015

Bruinooge, S. S., Pickard, T. A., Vogel, W., Hanley, A., Schenkel, C., Garrett-Mayer, E.,…Williams, S. F. (2018). Understanding the role of advanced practice providers in oncology in the United States. Journal of Oncology Practice, 14(9), e518–e532. https://doi.org/10.1200/jop.18.00181

Campbell, K., Chadha, N., Dimri, S., Wang, W., & Li, E. (2022). G-CSF primary prophylaxis use and outcomes in patients receiving chemotherapy at intermediate risk for febrile neutropenia: A scoping review. Expert Review of Hematology, 15(7), 619–633. https://doi.org/10.1080/17474086.2022.2093712

Chen, W., Boras, B., Sung, T., Hu, W., Spilker, M. E., & D’Argenio, D. Z. (2020). Predicting chemotherapy-induced neutropenia and granulocyte colony-stimulating factor response using model-based in vitro to clinical translation. The AAPS Journal, 22(6), 143. https://doi.org/10.1208/s12248-020-00529-x

Cheng, A. C., & Levy, M. A. (2019). Measures of treatment workload for patients with breast cancer. JCO Clinical Cancer Informatics, 3, 1–10. https://doi.org/10.1200/cci.18.00122

Coherus BioSciences. (2022). Udenyca (pegfilgrastim-cbqv) package insert. https://udenyca.com/hcp/wp-content/pdfs/udenyca-pi.pdf

Cooksley, T., Font, C., Scotte, F., Escalante, C., Johnson, L., Anderson, R., & Rapoport, B. (2021). Emerging challenges in the evaluation of fever in cancer patients at risk of febrile neutropenia in the era of COVID-19: A MASCC position paper. Supportive Care in Cancer, 29(2), 1129–1138. https://doi.org/10.1007/s00520-020-05906-y

Crawford, J., Moore, D. C., Morrison, V. A., & Dale, D. (2021). Use of prophylactic pegfilgrastim for chemotherapy-induced neutropenia in the US: A review of adherence to present guidelines for usage. Cancer Treatment and Research Communications, 29, 100466. https://doi.org/10.1016/j.ctarc.2021.100466

Curigliano, G., Banerjee, S., Cervantes, A., Garassino, M. C., Garrido, P., Girard, N.,...Pentheroudakis, G. (2020). Managing cancer patients during the COVID-19 pandemic: An ESMO multidisciplinary expert consensus. Annals of Oncology, 31(10), 1320–1335. https://doi.org/10.1016/j.annonc.2020.07.010

Dang, A., Gjolaj, L. N., Whitman, M., & Fernandez, G. (2018). Using process improvement tools to improve the care of patients with neutropenic fever in the emergency room. Journal of Oncology Practice, 14(1), e73–e81. https://doi.org/10.1200/JOP.2017.026054

Eckstrom, J., Bartels, T., Abraham, I., Patel, H., Elquza, E., Scott, A. J.,...McBride, A. (2019). A single-arm, retrospective analysis of the incidence of febrile neutropenia using same-day versus next-day pegfilgrastim in patients with gastrointestinal cancers treated with FOLFOX or FOLFIRI. Supportive Care in Cancer, 27(3), 873–878. https://doi.org/10.1007/s00520-018-4373-0

Elting, L. S., Xu, Y., Chavez-MacGregor, M., & Giordano, S. H. (2016). Granulocyte growth factor use in elderly patients with non-Hodgkin’s lymphoma in the United States: Adherence to guidelines and comparative effectiveness. Supportive Care in Cancer, 24(6), 2695–2706. https://doi.org/10.1007/s00520-016-3079-4

Epstein, R. S., Aapro, M. S., Basu Roy, U. K., Salimi, T., Krenitsky, J., Leone-Perkins, M. L.,...Crawford, J. (2020). Patient burden and real-world management of chemotherapy-induced myelosuppression: Results from an online survey of patients with solid tumors. Advances in Therapy, 37(8), 3606–3618. https://doi.org/10.1007/s12325-020-01419-6

Epstein, R. S., Nelms, J., Moran, D., Girman, C., Huang, H., & Chioda, M. (2022). Treatment patterns and burden of myelosuppression for patients with small cell lung cancer: A SEER-Medicare study. Cancer Treatment and Research Communications, 31, 100555. https://doi.org/10.1016/j.ctarc.2022.100555

European Society for Medical Oncology. (2023). Supportive care strategies during the COVID-19 pandemic. https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic/supportive-care-in-the-covid-19-era

Falchook, G., Coleman, R. L., Roszak, A., Behbakht, K., Matulonis, U., Ray-Coquard, I.,...Schilder, R. J. (2019). Alisertib in combination with weekly paclitaxel in patients with advanced breast cancer or recurrent ovarian cancer: A randomized clinical trial. JAMA Oncology, 5(1), e183773. https://doi.org/10.1001/jamaoncol.2018.3773

Fresenius Kabi. (2022). Stimufend (pegfilgrastim-fpgk) package insert. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761173Orig1s000correctedlbl.pdf

Goyal, R. K., Jain, P., Nagar, S. P., Le, H., Kabadi, S. M., Davis, K.,…Wang, M. (2021a). Real-world evidence on survival, adverse events, and health care burden in Medicare patients with mantle cell lymphoma. Leukemia & Lymphoma, 62(6), 1325–1334. https://doi.org/10.1080/10428194.2021.1919662

Goyal, R. K., Nagar, S. P., Kabadi, S. M., Le, H., Davis, K. L., & Kaye, J. A. (2021b). Overall survival, adverse events, and economic burden in patients with chronic lymphocytic leukemia receiving systemic therapy: Real-world evidence from the Medicare population. Cancer Medicine, 10(8), 2690–2702. https://doi.org/10.1002/cam4.3855

Griffith, N., McBride, A., Stevenson, J. G., & Green, L. (2014). Formulary selection criteria for biosimilars: Considerations for US health-system pharmacists. Hospital Pharmacy, 49(9), 813–825. https://doi.org/10.1310/hpj4909-813

Griffiths, E. A., Alwan, L. M., Bachiashvili, K., Brown, A., Cool, R., Curtin, P.,…Becker, P. S. (2020). Considerations for use of hematopoietic growth factors in patients with cancer related to the COVID-19 pandemic. Journal of the National Comprehensive Cancer Network, 19(13), 18–21. https://doi.org/10.6004/jnccn.2020.7610

Gupta, A., Abbasi, B., & Gupta, S. (2019). Management of chemotherapy-induced neutropenia – An unmet clinical need. American Journal of Biomedical Science & Research, 4(5), 313–318. http://dx.doi.org/10.34297/AJBSR.2019.04.000823

Hauber, A. B., Mange, B., Price, M. A., Wolin, D., Bensink, M., Kaye, J. A., & Chandler, D. (2018). Administration options for pegfilgrastim prophylaxis: Patient and physician preferences from a cross-sectional survey. Supportive Care in Cancer, 26(1), 251–260. https://doi.org/10.1007/s00520-017-3841-2

Hawkins, A., Murphy, A., McNamara, M., Gawade, P. L., Belani, R., & Kelsh, M. A. (2020). A survey of oncologists’ perceptions and opinions regarding the use of granulocyte colony-stimulating factors. Journal of Cancer Education, 35(1), 178–186. https://doi.org/10.1007/s13187-019-01638-8

Hawley, E. L., Loney, M., & Wiece, M. (2011). Development of tools and processes to improve treatment times in patients with febrile neutropenia. Clinical Journal of Oncology Nursing, 15(5), E53–E57. https://doi.org/10.1188/11.CJON.E53-E57

Humphreys, S. Z., Geller, R. B., & Walden, P. (2022). Pegfilgrastim biosimilars in US supportive oncology: A narrative review of administration options and economic considerations to maximize patient benefit. Oncology and Therapy, 10(2), 351–361. https://doi.org/10.1007/s40487-022-00207-2

Jee, J., Foote, M. B., Lumish, M., Stonestrom, A. J., Wills, B., Narendra, V.,…Pessin, M. S. (2020). Chemotherapy and COVID-19 outcomes in patients with cancer. Journal of Clinical Oncology, 38(30), 3538–3546. https://doi.org/10.1200/JCO.20.01307

Jee, J., Stonestrom, A. J., Devlin, S., Nguyentran, T., Wills, B., Narendra, V.,…Daniyan, A. F. (2021). Oncologic immunomodulatory agents in patients with cancer and COVID-19. Scientific Reports, 11(1), 4814. https://doi.org/10.1038/s41598-021-84137-5

Johnson, G. D., Moore, K., & Fortner, B. (2007). Baseline evaluation of the AIM Higher Initiative: Establishing the mark from which to measure. Oncology Nursing Forum, 34(3), 729–734. https://doi.org/10.1188/07.ONF.729-734

Johnson, P., Bancroft, T., Barron, R., Legg, J., Li, X., Watson, H.,…Marshall, D. A. (2014). Discrete choice experiment to estimate breast cancer patients’ preferences and willingness to pay for prophylactic granulocyte colony-stimulating factors. Value in Health, 17(4), 380–389. https://doi.org/10.1016/j.jval.2014.01.002

Kashiv BioSciences. (2022). Releuko (filgrastim-ayow) package insert. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761082s000lbl.pdf

Kitchen, K., & Mosier, M. C. (2022). Real-world febrile neutropenia rates with same-day versus next-day pegfilgrastim after myelosuppressive chemotherapy. Future Oncology, 18(23), 2551–2560. https://doi.org/10.2217/fon-2022-0365

Knobloch, M. J., Musuuza, J., Baubie, K., Saban, K. L., Suda, K. J., & Safdar, N. (2021). Nurse practitioners as antibiotic stewards: Examining prescribing patterns and perceptions. American Journal of Infection Control, 49(8), 1052–1057. https://doi.org/10.1016/j.ajic.2021.01.018

Lamure, S., Dulery, R., Delord, M., Di Blasi, R., Chauchet, A., Hueso, T.,…Thieblemont, C. (2021). Abstract S09-02: High incidence of persistent COVID-19 among patients with lymphoma treated with B-cell depleting immunotherapy. Clinical Cancer Research, 27(6_Supplement), S09–S02. https://doi.org/10.1158/1557-3265.COVID-19-21-S09-02

Li, E., Mezzio, D. J., Campbell, D., Campbell, K., & Lyman, G. H. (2021). Primary prophylaxis with biosimilar filgrastim for patients at intermediate risk for febrile neutropenia: A cost-effectiveness analysis. JCO Oncology Practice, 17(8), e1235–e1245. https://doi.org/10.1200/OP.20.01047

Li, S., Liu, J., Bowers, C., Garawin, T. A. F. S., Kim, C., Bensink, M. E., & Chandler, D. B. (2020). Febrile neutropenia-related care and associated costs in elderly patients with breast cancer, lung cancer, or non-Hodgkin lymphoma. Supportive Care in Cancer, 28(1), 113–122. https://doi.org/10.1007/s00520-019-04795-0

Lukes, T., Schjodt, K., & Struwe, L. (2019). Implementation of a nursing based order set: Improved antibiotic administration times for pediatric ED patients with therapy-induced neutropenia and fever. Journal of Pediatric Nursing, 46, 78–82. https://doi.org/10.1016/j.pedn.2019.02.028

Marion, S., Tzivelekis, S., Darden, C., Price, M. A., Sherif, B., Garcia, J., Kaye, J. A., & Chandler, D. (2016). “Same-day” administration of pegfilgrastim following myelosuppressive chemotherapy: Clinical practice and provider rationale. Supportive Care in Cancer, 24(9), 3889–3896. https://doi.org/10.1007/s00520-016-3193-3

Matera, R. M., Relias, V., & Saif, M. W. (2021). Safety and efficacy of same-day administration of pegfilgrastim in patients receiving chemotherapy for gastrointestinal malignancies. Cancer Medicine Journal, 4(1), 6–11.

Metz, M., Semsek, D., Rogmans, G., Hutzschenreuter, U., Fietz, T., Harde, J.,…Potthoff, K. (2021). Patient, nurse, and physician preferences: Final results of the CONVENIENCE study evaluating pegfilgrastim prophylaxis via pre-filled syringe or on-body injector in cancer patients. Supportive Care in Cancer, 29(11), 6633–6643. https://doi.org/10.1007/s00520-021-06230-9

Moore, K., Johnson, G., Fortner, B. V., & Houts, A. C. (2008). The AIM Higher Initiative: New procedures implemented for assessment, information, and management of chemotherapy toxicities in community oncology clinics. Clinical Journal of Oncology Nursing, 12(2), 229–238. https://doi.org/10.1188/08.CJON.229-238

Mylan. (2021). Fulphila (pegfilgrastim-jmdb) package insert. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=3ea915d7-2feb-4e75-91f7-913c965b7d8a

National Comprehensive Cancer Network. (2022). NCCN Clinical Practice Guidelines in Oncology: Hematopoietic growth factors. Version 1.2023. https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1493

Nordvig, J., Aagaard, T., Daugaard, G., Brown, P., Sengeløv, H., Lundgren, J., & Helleberg, M. (2018). Febrile neutropenia and long-term risk of infection among patients treated with chemotherapy for malignant diseases. Open Forum Infectious Diseases, 5(10), ofy255. https://doi.org/10.1093/ofid/ofy255

Otremba, B., Hielscher, C., Petersen, V., & Petrik, C. (2018). Home administration of filgrastim (Nivestim™) in primary prophylaxis of chemotherapy-induced febrile neutropenia. Patient Preference and Adherence, 12, 2179–2186. https://doi.org/10.2147/PPA.S168029

Patel, R., & Saif, M. W. (2020). Pancreatic cancer during COVID-19 pandemic: To treat or not to treat? Journal of the Pancreas, 21(2), 27–28. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201379/

Pfizer. (2021). Nyvepria (pegfilgrastim-apgf) package insert. https://labeling.pfizer.com/ShowLabeling.aspx?id=13622

Pfizer. (2023). Nivestym (filgrastim-aafi) package insert. https://labeling.pfizer.com/ShowLabeling.aspx?id=10899

Rasmy, A., Amal, A., Fotih, S., & Selwi, W. (2016). Febrile neutropenia in cancer patient: Epidemiology, microbiology, pathophysiology and management. Journal of Cancer Prevention & Current Research, 5(3), 273–278. https://doi.org/10.15406/jcpcr.2016.05.00165

Reynolds, R. B., & McCoy, K. (2016). The role of advanced practice providers in interdisciplinary oncology care in the United States. Chinese Clinical Oncology, 5(3), 44. https://doi.org/10.21037/cco.2016.05.01

Rigdon, A. S. (2010). Development of patient education for older adults receiving chemotherapy. Clinical Journal of Oncology Nursing, 14(4), 433–441. https://doi.org/10.1188/10.CJON.433-441

Sandoz. (2021). Ziextenzo (pegfilgrastim-bmez) package insert. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761045s006lbl.pdf

Sandoz. (2022). Zarxio (filgrastim-sndz) package insert. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c0d1c22b-566b-4776-bdbf-00f96dad0cae&type=display

Schelenz, S., Giles, D., & Abdallah, S. (2012). Epidemiology, management and economic impact of febrile neutropenia in oncology patients receiving routine care at a regional UK cancer centre. Annals of Oncology, 23(7), 1889–1893. https://doi.org/10.1093/annonc/mdr520

Schenfeld, J., Gong, T., Henry, D., Kelsh, M., Gawade, P., Peng, Y.,…Li, S. (2022). Patterns of primary prophylactic granulocyte colony-stimulating factor use in older Medicare patients with cancer receiving myelosuppressive chemotherapy. Supportive Care in Cancer, 30(7), 6327–6338. https://doi.org/10.1007/s00520-022-06967-x

Sharma, P., Kimler, B. F., O’Dea, A., Nye, L., Wang, Y. Y., Yoder, R.,…Khan, Q. (2021). Randomized phase II trial of anthracycline-free and anthracycline-containing neoadjuvant carboplatin chemotherapy regimens in stage I-III triple-negative breast cancer (NeoSTOP). Clinical Cancer Research, 27(4), 975–982. https://doi.org/10.1158/1078-0432.CCR-20-3646

Sosa, R., Li, S., Molony, J. T., Liu, J., Stryker, S., & Collins, A. J. (2017). Use of prophylactic growth factors and antimicrobials in elderly patients with cancer: A review of the Medicare database. Supportive Care in Cancer, 25(10), 3123–3132. https://doi.org/10.1007/s00520-017-3720-x

Stephens, J. M., Bensink, M., Bowers, C., & Hollenbeak, C. S. (2019). Risks and consequences of travel burden on prophylactic granulocyte colony-stimulating factor administration and incidence of febrile neutropenia in an aged Medicare population. Current Medical Research and Opinion, 35(2), 229–240. https://doi.org/10.1080/03007995.2018.1465906

Sureda, A., Domingo-Domenech, E., & Gautam, A. (2019). Neutropenia during frontline treatment of advanced Hodgkin lymphoma: Incidence, risk factors, and management. Critical Reviews in Oncology/Hematology, 138, 1–5. https://doi.org/10.1016/j.critrevonc.2019.03.016

Teva. (2019). Granix (tbo-filgrastim) package insert. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125294s046lbl.pdf

Weycker, D., Doroff, R., Hanau, A., Bowers, C., Belani, R., Chandler, D.,…Lyman, G. H. (2019). Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice: A retrospective observational study. BMC Cancer, 19(1), 792. https://doi.org/10.1186/s12885-019-6010-9

Wijeratne, D. T., Wright, K., & Gyawali, B. (2021). Risk-stratifying treatment strategies for febrile neutropenia—Tools, tools everywhere, and not a single one that works? JCO Oncology Practice, 17(11), 651–654. https://doi.org/10.1200/OP.21.00148

Wilson, B. J., & Gardner, A. E. (2007). Nurses’ guide to understanding and implementing the National Comprehensive Cancer Network guidelines for myeloid growth factors. Oncology Nursing Forum, 34(2), 347–353. https://doi.org/10.1188/07.ONF.347-353

Wright, J. D., Neugut, A. I., Ananth, C. V., Lewin, S. N., Wilde, E. T., Lu, Y. S.,..Hershman, D. L. (2013). Deviations from guideline-based therapy for febrile neutropenia in cancer patients and their effect on outcomes. JAMA Internal Medicine, 173(7), 559–568. https://doi.org/10.1001/jamainternmed.2013.2921

Xie, J., Cao, J., Wang, J. F., Zhang, B. H., Zeng, X. H., Zheng, H.,…Hu, X. C. (2018). Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: An open-label, randomized, multicenter phase III study. Breast Cancer Research and Treatment, 168(2), 389–399. https://doi.org/10.1007/s10549-017-4609-6

Yarza, R., Bover, M., Paredes, D., López-López, F., Jara-Casas, D., Castelo-Loureiro, A.,…Gómez-Martín, C. (2020). SARS-CoV-2 infection in cancer patients undergoing active treatment: Analysis of clinical features and predictive factors for severe respiratory failure and death. European Journal of Cancer, 135, 242–250. https://doi.org/10.1016/j.ejca.2020.06.001

Ysebaert, L., Larcher, M., Compaci, G., Oberic, L., Sahnes, L., Banos, A.,…Despas, F. (2019). Oncology nurse phone calls halve the risk of reduced dose intensity of immunochemotherapy: Results of the randomized FORTIS study in chronic lymphocytic leukemia. Annals of Hematology, 98(4), 931–939. https://doi.org/10.1007/s00277-019-03631-z

Yucel, A., Skalicky, A., Eseyin, O. R., Yucel, E., Belani, R., & Bensink, M. (2021). Development and content validation of the Satisfaction and Experience Questionnaire for Granulocyte Colony-Stimulating Factor (SEQ-G-CSF). Journal of Patient-Reported Outcomes, 5(1), 10. https://doi.org/10.1186/s41687-020-00277-8

Zhang, A. W., Morjaria, S., Kaltsas, A., Hohl, T. M., Parameswaran, R., Patel, D.,…Taur, Y. (2022). The effect of neutropenia and filgrastim (G-CSF) on cancer patients with coronavirus disease 2019 (COVID-19) infection. Clinical Infectious Diseases, 74(4), 567–574. https://doi.org/10.1093/cid/ciab534